Entresto (sacubitril/valsartan) - Novartis, ROVI Pharmaceuticals Laboratories
SUPERIOR – Sacubitril/Valsartan for Preventing Recurrence of Atrial Fibrillation After Catheter Ablation in Patients With Hypertension: A Multicenter, Randomized Controlled Trial (AHA 2026) - Oct 8, 2026 - Pres time: Nov 8, 2026; 04:00 PM - 04:10 PM; Location: Center Stage‚ North Hall‚ Level 3; In-Person; No abstract available 
Clinical • Late-breaking abstract • Atrial Fibrillation • Cardiovascular • Hypertension
https://eppro01.ativ.me/web/page.php?page=session&project=AHA26&id=P16211
 
Jiguang Wang; Wei Zhang
 
Oct 8, 2026
 
Prev Next